Loss of JunB has been observed in human leukemia and lymphoma, but it remains unknown, whether this loss is relevant to disease progression. Here, we investigated the consequences of JunB deficiency using Abelson-induced B-lymphoid leukemia as a model system. Mice deficient in JunB expression succumbed to Abelson-induced leukemia with increased incidence and significantly reduced latency. Similarly, bcr/abl p185-transformed JunB-deficient (junB
Introduction
Activator protein-1 (AP-1) is a dimeric transcription factor composed of members of the Jun family (c-Jun, JunB and JunD), which form homodimers or heterodimers with members of the Fos family (c-Fos, Fra-1, Fra-2 and FosB) and activating transcription factor (ATF) proteins (Hai and Curran, 1991) . AP-1 modulates transcription by binding to TPA-response element (TRE) or cAMP-response element (CRE) consensus elements and is involved in proliferation, differentiation and apoptosis (Lee et al., 1987; Halazonetis et al., 1988) . AP-1 members may elicit divergent and even antagonistic effects via a cell-type-specific regulation of target genes (Szabowski et al., 2000; Mechta-Grigoriou et al., 2001) .
Lack of JunB causes death of the embryo during midgestation (Schorpp-Kistner et al., 1999) . Embryonic viability can be rescued in two ways: (i) by intercrossing junB À/À with Ubi-junB transgenic mice and (ii) by a conditional gene-targeting approach, which allows for specific ablation of JunB in the embryo, but not in extraembryonic tissues (Kenner et al., 2004) . Observations in these models suggest an important role of JunB in hematopoesis. In junB À/À mice intercrossed with UbijunB mice, silencing of the transgene is associated with myeloid hyperproliferation, which progresses to a chronic myeloid leukemia (CML)-like disease (Passegue et al., 2001) . A similar phenotype is observed upon conditional deletion of junB in the embryo (junB D/D mice) (Passegue et al., 2004) . The relevance of these findings is underlined by the fact that silencing of junB is also observed in human CML (Yang et al., 2003) . In addition, JunB is altered in human lymphoid malignancies. JunB is overexpressed in Hodgkin's lymphoma and in T-cell tumors, but only expressed at low levels or entirely missing in B-lymphoid malignancies (Mao et al., 2003; Szremska et al., 2003; Rassidakis et al., 2005) . This observation is remarkable, as AP-1 family members are generally expressed at high levels in transformed cells (Wu et al., 1990) . We recently demonstrated that the forced expression of JunB in Ubi-junB mice counteracted the development of Abelson-induced leukemia and that JunB acts as a tumor suppressor in the initial phase of leukemogenesis (Szremska et al., 2003) . In the present study, we investigated the consequences of JunB deficiency for the onset and progression of a B-lymphoid leukemia in vivo.
Results

JunB
D/D mice are highly susceptible to Abelson-induced B-lymphoid leukemia To study the consequences of JunB deficiency in the development of B-lymphoid leukemia, we used conditional knockout mice (junB fl/fl ) crossed to epiblast-specific MORE-Cre mice (Kenner et al., 2004) . These mice express JunB solely in the placenta. B-lymphoid leukemia was inflicted by a single exposure of newborn mice to the Ab-MuLV retrovirus.
Fourteen junB wt/fl and eight junB D/D mice were injected with Ab-MuLV. Moreover, we injected six junB D/D mice with sterile saline to control for the myeloid leukemia that evolves in these mice. Abelson-induced leukemia emerged with a 100% incidence in junB D/D mice within 13 weeks (Figure 1a) . During this time, only six of the 14 junB wt/fl mice (42.9%) were affected, the remaining mice stayed disease free up to 18 weeks (Po0.001). At this time, the first signs of myelo-proliferative disease were detectable in the saline-injected junB D/D mice, and the experiment was terminated. We verified that the retrovirally induced leukemia was solely of lymphoid origin by FACS analysis of bone marrow, lymph nodes and spleen of the diseased animals. As expected, the infiltrating leukemic cells solely expressed B-lymphoid markers (CD19 and B220) (Figure 1b) .
The facilitated onset of junB D/D B-lymphoid leukemia is a cell intrinsic phenomenon Leukemia in an organism evolves despite the presence of the immune system that eliminates transformed cells. The accelerated leukemia development in junB D/D mice may be related to a defective immune system that fails to efficiently eliminate virally infected or transformed cells. To test this, we generated pMSCV-bcr/abl p185-IRES-GFP-transformed cell lines (CD19 þ /CD43 þ /B220 þ ). Abelson-transformed junB D/D cells have a proliferative advantage As AP-1 transcription factors control cell proliferation and apoptosis, differences in leukemia formation may be due to an impaired apoptosis in junB D/D cells; thus, we studied apoptosis in response to serum withdrawal (Figure 2a ), g-irradiation or ultra-violet (UV) irradiation (data not shown). Irrespective of the stimulus used, we failed to detect any differences. As p185 bcr/abl -transformed cells respond with apoptosis to interferon treatment (Grawunder et al., 1993) and interferon-g is a key factor in tumor surveillance, we tested survival in the presence of interferon-g (IFN-g; Kaplan et al., 1998; Shankaran et al., 2001 (Figure 2c ). Finally, the expression of bcl 2 , bcl x and bax was reasonably similar in these cell lines as was the expression of c-Jun and c-Fos, and the upstream kinases JNK1 and JNK2 ( Figure 2d ). Interferon has been used to treat patients, but has recently been replaced by the tyrosine kinase inhibitor imatinib (Deininger et al., 2005) . Growth inhibition by imatinib was also unchanged in junB
In view of these findings, it seems unlikely that alterations in the apoptotic response of junB D/D cells contribute to the increased malignancy. In contrast, analysis of cell growth consistently revealed an increased proliferation rate in junB 
D/D cells lose p16 INK4a and maintain cdk6 expression Cdks are modulators of tumor progression. As the upregulation of cdk6 has so far not been reported as a consequence of junB deficiency, we ruled out that the enhanced cdk6 levels were already present in nontransformed junB D/D cells. We analysed whole spleen extracts, CD19 MACS-purified primary B-lymphoid cells and primary mouse embryonic fibroblasts (MEFs) of junB D/D and wild-type mice by immunoblotting. As depicted in Figure 4a and b, we failed to detect any differences in cdk6 and cdk4 expression. In contrast, a strong cdk6 expression was found in all 15 junB D/D cell lines. The closely related cell cycle kinase cdk4 was not affected (Figure 4c) . We determined the time course of cdk6 and p16
INK4a expression after the initial transformation event by the following approach: JunB D/D and junB fl/fl fetal liver cell suspensions were infected with the pMSCV-bcr/abl p185-IRES-GFP retrovirus, and cdk6 expression was monitored by Western blotting after 3, 5 and 6 weeks ( Figure 4d ). Whereas cdk6 expression rapidly ceased in junB wt/fl cells, high levels of cdk6 were maintained in junB D/D cells resulting in a striking difference of cdk6 protein expression after 4-6 weeks. Reverse transcription-PCR (RT-PCR) analysis showed that the differences in cdk6 expression occurred at the mRNA level; cdk6 was detectable at increased levels in junB D/D cells. Moreover, junB D/D cells lacked transcripts for p16, whereas p21 and p27 transcripts were detectable at comparable amounts in wild-type and junB (Figure 5a ). Similarly, injection of the cells into nu/nu mice did not result in any differences in tumor development (Figure 5b ). One week after the exposure to the oncogene, the transformed cells still expressed cdk6 and p16
INK4a at comparable levels ( Figure 5c ). Interestingly, if the same fetal liver cell preparations were propagated in vitro and tested 6 weeks after the initial transformation event, the significant growth advantage of the junB D/D had emerged (data not shown). Accordingly, at that time point, the transformed junB D/D cells had acquired the increased aggressive potential and induced tumors in nu/nu mice with statistically significant increased incidence and reduced latency (Po0.001; Figure 5d ). At this stage, alterations in cdk6 and p16
INK4a levels were readily detectable (Figure 5e ). Alterations in p16
INK4a levels could be accounted for by methylation of the p16 promoter region in junB D/D cells (Figure 5f ). Our observations indicate that transformation by p185 bcr/abl induces an evolutionary process that, in the absence of JunB, allows for the emergence of highly malignant tumor cells.
The selection process occurring in junB D/D cells is irreversible Finally, we asked whether re-expression of JunB was able to revert the increased malignancy of junB D/D cells and re-establish normal levels of cdk6 and p16
INK4a
.
JunB
D/D cells (two different clones) were stably infected with pMSCV-JunB-puro or the empty vector as a control. Stable cell lines that had high levels of JunB were readily obtained (Figure 6a) . However, the forced expression of JunB did not affect the expression of cdk6 or of p16
INK4a
. Accordingly, cell proliferation did not change in cells engineered to overexpress JunB (Figure 6b) . Similarly, these cells were indistinguishable from their parental cell lines when assessed for their ability to give rise to tumors in nu/nu mice (Figure 6c ).
Discussion
Alterations of JunB expression are frequently observed in human leukemia and lymphoma. JunB is expressed at high levels in Hodgkin's lymphoma and T-cell malignancies (Mao et al., 2003; Rassidakis et al., 2005) . In contrast, it is not detectable in most human B-lymphoid malignancies and silenced in advanced stages of myeloid leukemia (Yang et al., 2003; Szremska et al., 2003) . We undertook this study to investigate the consequences and the significance of JunB loss for tumor development in the B-lymphoid lineage. In contrast to myeloid cells, the sole deletion or lack of JunB in B-lymphoid cells did not induce a lymphoproliferative disease. The difference became evident upon oncogenic transformation: the loss of JunB enhanced disease incidence and accelerated leukemia progression in the B-lymphoid lineage. Our findings are in agreement with a previous observation that showed that the forced expression of JunB in the B-lymphoid lineage suppressed and counteracted Abelsoninduced leukemia formation (Szremska et al., 2003) . One key feature of tumor cells is the ability to evade apoptosis. There is evidence for AP-1 transcription factors in the general regulation of apoptosis and also particularly in cancer formation (Eferl et al., 2003) . In the case of B-lymphoid leukemia, JunB does not appear to contribute to apoptosis or is compensated for by other AP-1 members. Irrespective of the stimuli used, we consistently failed to observe any difference. Moreover, there was no sign of elevated apoptotic cell numbers in the HE stains of diseased animals. We therefore rule out that loss of JunB interferes with the apoptotic behavior of leukemic cells.
Instead, the proliferative capacity of transformed junB
cells was increased in conjunction with alterations in cell cycle components. D-type cyclins associate with cdk4 or cdk6 to form active complexes, which phosphorylate transcriptional repressors of the Rb-family (Ezhevsky et al., 1997) . Surprisingly, we observed decreased expression levels of the D-type cyclins D2 and D3 in junB D/D cells. However, these changes did not translate into diminished kinase activity of cdk4/cdk6. In contrast, we found elevated cdk6-dependent kinase activity in junB D/D cells. We reasoned that the decreased D-type cyclin levels are most likely compensated for by the decreased expression of the inhibitor proteins p21, p27 and p16, which are consistently lower. Whereas the alterations in p16 protein levels are due to transcriptional changes based on promoter hypermethylation, we did not see significant changes in p21 or p27 mRNA. Both proteins are regulated at a post-transcriptional level. Among the kinases that regulate p27 degradation is cdk2 itself (Sheaff et al., 1997) . Phosphorylation of p27 by cdk2 induces ubiquitylation of the protein, and this may partially account for the reduced p27 protein levels in junB D/D cells that indeed show elevated cdk2 kinase activity. The most obvious difference between junB D/D and wild-type cells resides in the significantly enhanced expression of cdk6 in junB D/D cells. The difference in cdk6 expression is a consequence of oncogenic transformation, and is not detectable in non-transformed junB D/D cells. Finally, it is worth noting that loss of cdk6 is a response elicited by the BCR-ABL oncogene that is contingent on JunB: in the presence of JunB, BCR-ABL-induced transformation was associated with downregulated expression of cdk6, whereas in its absence expression of cdk6 was preserved. The significance of this finding is currently unclear: overexpression of cdk6 has been implicated as a causative mechanism in human B-cell lymphoma (Corcoran et al., 1999) . However, cellular transformation by cdk6 requires the presence of its cognate regulatory component, in particular cyclin D3, because cdks are inactive in the absence of a D-type cyclin (Baldin et al., 1993; Diehl and Sherr, 1997) . As mentioned, levels of cyclin D2 and D3, however, were downregulated. Thus, further studies are required to unravel the significance of cdk6 expression.
It is generally established that a single oncogene does not suffice to induce tumor formation. Additional genomic hits have to accumulate to establish a malignant phenotype (Hanahan and Weinberg, 2000; Vogelstein and Kinzler, 2004) . In many instances, mutations providing positive growth stimuli are combined with hits, leading to loss of tumor suppressors, which act as gatekeepers. Here we identified JunB as a gatekeeper; its absence allowed for the gradual emergence of highly aggressive transformed cells. Conceptually, oncogenic transformation can be considered as a trigger, similar to a stimulus inducing a differentiation program. Some of these reactions are irreversible in nature. At the biochemical level, hysteresis and bistability are characteristic features of MAP kinase (MAPK) cascades and AP-1 complexes (Marique and Werenne, 2001; Markevich et al., 2004) ; if a new equilibrium has emerged, it is very difficult or impossible to return the system to its original state. Similarly, the highly aggressive phenotype that emerged in the absence of JunB was resistant to reversion upon re-expression of JunB. This may partly be explained by the irreversible nature of the increased methylation of the p16 promoter. Loss of JunB is frequently observed in human tumors of the B-lymphoid lineage, and its gene is silenced in advanced stages of myeloid leukemia (Mao et al., 2002; Szremska et al., 2003; Yang et al., 2003) . We propose that any therapeutic strategy that aims at elevating JunB expression is doomed to fail. Loss of JunB rather is to be considered a prognostic marker that is indicative of a rapidly progressing disease.
Materials and methods
Mice and infection of neonatal mice with Ab-MuLV C57BL/6J (C57BL/6) JunB fl/fl , More-Cre mice, nu/nu and RAG2 À/À mice were described previously (Shinkai et al., 1992; Kenner et al., 2004) . Animal experiments were performed in accordance with protocols approved by the Animal Welfare Committee (MUW). Newborn mice were injected intraperitoneally with 50 ml of replication-incompetent ecotropic retrovirus encoding for Ab-MuLV (Sexl et al., 2000) . Sick mice were killed. Peripheral blood, lymphoid and hematopoietic organs were analysed for leukemic cells by FACS and by histopathology. The antibodies used included B220 (RA3-6B2), CD19 (1D3) and CD43 (1B11).
Preparation of primary cells, infection of fetal liver cells and cell lines
Fetal liver cell suspensions (ED14) were prepared and infected with viral supernatant (pMSCV-bcr/abl p185-IRES-GFP) derived from Phoenix ecotropic cells (Szremska et al., 2003) . Established p185 bcr/abl -transformed cell lines were infected overnight with pMSCV-puro, pMSCV-cdk6-DN-puro, or pMSCV-junB-puro viral supernatant and selected with 2 mg/ ml puromycin (Sigma, Vienna, Austria). Naı¨ve B-cells were purified with MACS CD19-coupled beads (Miltenyi Biotech, Bergisch Gladbach, Germany).
Transplantation of tumor cells into RAG2
À/À and nu/nu mice For tail vein injections, 1 Â 10 6 cells from six independently derived pMSCV-bcr/abl p185-IRES-GFP-transformed junB Protein analysis, Western blotting and kinase assays Cells were lysed as described previously (Szremska et al., 2003) . Proteins (60 mg) were separated on SDS-polyacrylamide gels and transferred onto Immobilon membranes. Membranes were probed with a-cdk6 (sc-177), cdk4 (sc-260), p16 (sc-1207) and JunB (sc-73x) (Santa Cruz Biotechnologies Inc., Santa Cruz, CA, USA), p19 (Ab80; Abcam Inc., Cambridge, UK) and b-actin (Sigma A2228). For kinase assays, 800 mg of protein lysate was immunoprecipitated with antibodies against cdk2 (sc-163), cdk4 (sc-260) and cdk6 (a generous gift from M Malumbres, CNIO) as described (Sexl et al., 1999) . The kinase reaction was initiated by adding 10 mCi of [g-32 p]ATP (Amersham Biosciences, GE Health care, Munich, Germany) and 1 mg histone H1 (Roche Diagnostics, Vienna, Austria) per sample for cdk2 or 1 mg p56Rb (QED Bioscience, San Diego, CA, USA) for cdk4 and cdk6, respectively.
RNA isolation, semiquantitative RT-PCR and methylationspecific PCR RNA was isolated with TRIZOL (TRIreagent, Sigma). Firststrand cDNA synthesis and PCR amplification were performed with an RT-PCR kit (GeneAmp RNA PCR Kit). Primer sequences are available on request. The reactions were performed using AmpliTaq DNA Polymerase Kit (GeneAmp RNA PCR Kit). For methylation-specific PCR (MSP), 1 mg of purified genomic DNA was used for chemical modification by sodium bisulfite treatment as reported previously (Herman et al., 1996) . The methylation status of the region 5 0 to the coding sequence of the genes p16, p21, p27, cdk4, cdk6 and JunB was analysed by MSP. MSP primer sequences for p16 were used as reported previously (Wolff et al., 2003) . For the genes p21, p27, cdk4, cdk6 and JunB, MSP primer sequences were designed using the online program MethPrimer (Li and Dahiya, 2002) and are available upon request.
Statistical analysis
Statistical comparisons were made by using Student's t-test and the w 2 -test. Kaplan-Meier plots were analysed using the log-rank test. Concentration-response curves were subjected to nonlinear, least-squares curve fitting.
